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OBJECTIVES: The Cost Of Diabetes Type 2 In Poland
(CODIP) is multicenter, bottom-up designed, retrospec-
tive study aimed at evaluation of total cost of diabetes
type 2 in Poland. Study design reﬂects that of CODE 2
(Cost Of Diabetes in Europe Type 2) and allows for inter-
national comparison. METHODS: Three hundred three
patients diagnosed with type 2 diabetes mellitus (mean
age: 61, mean time from diagnosis: 10,86 year, males:
49%) were randomly selected from out-patients charts
databases and surveyed. Both patient and practitioner
questionnaires collected data from each patient on: clin-
ical characteristic, medical and other resources used,
quality of life. Total treatment costs were calculated using
drug retail and medical procedures prices. Indirect costs
were estimated by human capital approach. The impact
of complications on total costs was evaluated. Values 
are expressed in PLN and also presented in Euro value
(PPP value: €1 = 1.9 PLN). RESULTS: A total of 74.6%
patients presented comorbidities with coronary arteries
disease as most prevalent (20.5%). The total annual treat-
ment costs amounted to 6797 PLN (€3577), including
2460 PLN (€1295) of direct costs. The direct cost struc-
ture: 21% physicians consultations, 3% paramedics,
46% diabetic drug costs (insulin 63%, oral hypoglycemic
agents and glucagon 37%), hospital costs 29%, emer-
gency service 1%. Calculating expenditures for comor-
bidities direct costs increased up to 4390 PLN (€2310).
Mean cost for patients with no complications amounted
to 1892 PLN (€996). The indirect cost is mainly deter-
mined by early retirements or morbidity and relatives care
costs. CONCLUSIONS: Economic impact of diabetes
type 2 in Poland is considerable. Insulin prescription pat-
terns are responsible for large part of drug costs. Diabetes
complications are associated with signiﬁcant total costs
increase.
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OBJECTIVES: In a type 2 diabetes population, we cal-
culated retrospectively the hospital costs according to dif-
ferent body mass index (BMI). METHODS: We studied
a cohort (n = 2263) of type 2 diabetes patients in-
cluded up to February 2002 and having undergone at
least two visits. The cohort was stratiﬁed in 4 BMI 
groups calculated on the mean measured body weight:
18.5–24.9kg/m2 (normal), 25–29.9kg/m2 (overweight),
30–34.9kg/m2 (obese) and over 35kg/m2 (very obese).
Annual hospital costs per patient for each BMI group
were calculated by combining observed Health care
resource utilization and ofﬁcial costs data of the Diagno-
sis Related Group (DRG) system. Health care resource
considered and costs were related to management of 
diabetes (in-hospitalization, day care hospitalization) and
complications (myocardial infarction, angina pectoris,
transient ischaemic accident and stroke). RESULTS:
Number of patients per group was 399, 914, 625, and
325 for normal, overweight, obese, and very obese respec-
tively. Total annual hospital costs (in Euros) per patient
were 2357, 2645, 2779, and 2972 for normal, over-
weight, obese and very obese respectively. In each group,
the relative weight of in-hospitalization cost for manage-
ment of diabetes were 51.2%, 51%, 58.1%, and 64.4%
for normal, overweight, obese and very obese respec-
tively. In each group, the relative weight of cost of com-
plications were 8%, 10.8%, 7.3%, and 8.9% for normal,
overweight, obese and very obese respectively. CON-
CLUSIONS: We conﬁrm obese diabetic patients (BMI
above 25kg/m2) generate more hospital costs than non-
obese diabetic patients. According to the increase of BMI,
we note a progression of in-hospitalization costs for man-
agement of type 2 diabetes whereas the proportion of day
care hospitalization costs is decreasing. Higher is the
BMI, higher are costs dedicated to diabetes care. As oppo-
site, cost of complications remains stable whatever the
BMI. Prevention of complications in patient with high
BMI may be an explanation to this pattern of care.
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OBJECTIVES: To investigate determinants on use of
emergency department in elderly patients with DM. Dia-
betes mellitus (DM) is a common chronic condition that
affects about 10% elderly population in the US. The total
direct medical expenditures incurred by people with dia-
betes are estimated more than $44 billion. It is estimated
that individual over the age of 65 years account for
approximately two-thirds of all medical costs related to
diabetes. Despite fact that a number of studies have exam-
ined medical cost and service use in patients with DM,
little is know about use of emergency department 
in elderly patients with DM. METHODS: Using the
national representative data of Medicare Current Beneﬁ-
ciary Survey (MCBS) in 1999, 1646 fee-for-service
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patients aged 65 years or older with DM (ICD-9-CM
code = 250.xx) were identiﬁed. The personal informa-
tion on socio-demographic characteristics, self-perceived
health status, co-existing medical conditions and other
measures were from the MCBS survey. The use of emer-
gency department (ED) was measured by number of ED
visits. A multivariate count regression model was used 
in the analysis. RESULTS: Of 1646 patients, 57% were
female; 81% were white; and 57% were current smokers.
The average number of ED visits was 74 per 100 patients
(SD = ±14.5). There were 35 percents of these patients
who had at least 1 emergency department visit. The
results from the multivariate regression model show that
predictors of ED visits were current smoker, poor in 
self-perceived health status, with 3 or more difﬁculties in
activity of daily living, having cardiovascular diseases.
Gender, race, education, living arrangement, Medicaid
insurance status, and residence were not signiﬁcant
factors to predict ED visits while controlling other
factors. CONCLUSIONS: This study shows that smoking
cessation and improving management in co-exsiting car-
diovascular diseases in older patients with diabetes may
reduce preventable ED visits.
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OBJECTIVES: To obtain the incremental cost for avoid-
ing a transition from a diagnosed IGT to diabetes through
a treatment based in the use of the Acarbose drug com-
pared to the normal practice. METHODS: Modelisation
of the health and economic consequences (direct costs for
the health system), in a period of 40 months, of imple-
menting Acarbose or a non-drug treatment to a popula-
tion of 1000 subjects diagnosed of IGT. The efﬁcacy,
adverse events, and the follow up of the pharmacological
treatment data were obtained from a controlled clinical
trial: STOP-NIDDM. The resources’ cost data were
obtained from published studies focused on the Spanish
Health System. The differential resources’ use of both
treatments (visits, tests, etc.) was actually discussed with
an expert in diabetes. RESULTS: The incremental cost of
avoiding the transition to type 2 DM from a IGT state
with the pharmacological treatment based on the use of
Acarbose is about €3386, and the incremental cost per
year of diabetes avoided is about €1736. Additionally the
evaluated treatment has signiﬁcant results reducing car-
diovascular events. CONCLUSION: In order to evaluate
all the positive effects of the treatment, a longer-term cost-
beneﬁt analysis and a comparison of the pharmacologi-
cal treatment of Acarbose with other 2 DM prevention
alternatives (basically the ones related to the life style)
would be needed.
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OBJECTIVE: To compare the association of congestive
heart failure (CHF) risk between pioglitazone use and
insulin use in type 2 diabetes patients. METHODS:
Adults with type 2 diabetes who initiated pioglitazone 
or insulin (INS) treatment between January 1999 and
December 2001 were identiﬁed and an “index date”
assigned based on the ﬁrst antidiabetic drug prescription.
The sample was restricted to those continuously en-
rolled at least 12 months before and at least 3 months
after therapy initiation. Patients with CHF diagnosis 
or digoxin use in the preindex period, troglitazone use
during preindex or follow up, or any oral antidiabetic use
other than metformin or a sulfonylurea (ﬁnal 6 months
of preindex only) was excluded. INS patients were
matched (1 :1) to pioglitazone patients based on a differ-
ence of no more than ±0.01 in the estimated propensity
score for pioglitazone therapy; propensity was modeled
using logistic regression; controlling for demographics,
comorbidities, preindex utilization costs; and postindex
treatment duration. CHF risk (based on ≥1 diagnoses
during follow up) was examined using Cox proportional
hazards models. Further, risk of inpatient hospitalization
for CHF also was explored. RESULTS: A total of 1668
matched pairs were identiﬁed for pioglitazone vs. insulin
comparison. Mean patient age was 51 years; 51% were
male. Crude CHF incidence was higher in the INS group
(4.0% vs. 2.0% for INS group at 2 years, p = 0.001). In
Cox proportional hazards models controlling for age 
and preindex total Health care costs, 2-year CHF risk was
signiﬁcantly lower for the pioglitazone group (HR =
0.501, 95% CI = 0.331, 0.758; p = 0.001) than for 
the INS group; ﬁndings were similar for inpatient 
hospitalization for CHF (HR = 0.263, 95% CI = 0.135,
0.511; p = 0.0001). Differences were similar when 
pioglitazone monotherapy was compared with insulin.
CONCLUSION: Pioglitazone use appears to be associ-
ated with lower CHF risk versus INS use in type 2 
diabetes patients.
